Scientists modify Botox for the treatment of pain

(Press-News.org) Contact information: Clare Parkin
clare.parkin@sheffield.ac.uk
01-142-229-851
University of Sheffield
Scientists modify Botox for the treatment of pain A team of 22 scientists from 11 research institutes led by Professor Bazbek Davletov, now at the University of Sheffield, created and characterised a new molecule that was able to alleviate hypersensitivity to inflammatory pain.

The work is featured on the cover of the October 2013 issue of the scientific journal Bioconjugate Chemistry.

Professor Bazbek Davletov joined the Department of Biomedical Science in September last year from the Medical Research Council's Laboratory of Molecular Biology in Cambridge, where his team developed a new way of joining and rebuilding molecules.

By using elements of Clostridium botulinum and Clostridium tetani neurotoxins, commonly known as Botox and tetanus toxin respectively, the scientists were able to develop a molecule with new biomedical properties, without unwanted toxic effects.

While the Botox element is able to block neuronal communication – and therefore pain signals - for months, the tetanus component targets the central nervous system very effectively. The combination of the two elements is of great interest for neuroscience and can be applied to the treatment of several neurological disorders, particularly chronic pain conditions and epilepsy.

Botox and tetanus neurotoxins hold great promise for clinical applications, but their paralytic activity was a stumbling block until now. The team demonstrated that their newly engineered molecule is a potent non-paralysing neuronal blocker. Preclinical collaborative studies with Dr Enrico Ferrari at the University of Lincoln and Professor Stephen Hunt at University College London indicate usefulness of the new molecule for alleviation of inflammatory pain.

Professor Davletov added: "Currently painkillers relieve lingering pain only temporarily and often have unwanted side effects. A single injection of the new molecule at the site of pain could potentially relieve pain for many months in humans and this now needs to be tested. "We hope that the engineered molecule could improve the quality of life for those people who suffer from chronic pain. We are now negotiating transfer of the technology to a major pharmaceutical company."

Professor Davletov's team in the Department of Biomedical Science is now working not only on neuronal blockers tailored for various neurological conditions but also on developing new cancer drugs.

### Paper reference: Synthetic Self-Assembling Clostridial Chimera for Modulation of Sensory Functions Bioconjugate Chemistry, DOI: 10.1021/bc4003103 http://pubs.acs.org/action/showLargeCover?jcode=bcches&vol=24&issue=10

Modified Botox could be used for the treatment of chronic pain and epilepsy A single injection could relieve pain for months The research could improve the quality of life for people who suffer from chronic pain conditions Scientists have manufactured a new bio-therapeutic molecule that could be used to treat neurological disorders such as chronic pain and epilepsy.

Additional information University of Sheffield

With nearly 25,000 of the brightest students from 117 countries coming to learn alongside 1,209 of the world's best academics, it is clear why the University of Sheffield is one of the UK's leading universities. Staff and students at Sheffield are committed to helping discover and understand the causes of things - and propose solutions that have the power to transform the world we live in.

A member of the Russell Group, the University of Sheffield has a reputation for world-class teaching and research excellence across a wide range of disciplines. The University of Sheffield has been named University of the Year in the Times Higher Education Awards 2011 for its exceptional performance in research, teaching, access and business performance. In addition, the University has won four Queen's Anniversary Prizes (1998, 2000, 2002, 2007), recognising the outstanding contribution by universities and colleges to the United Kingdom's intellectual, economic, cultural and social life.

One of the markers of a leading university is the quality of its alumni and Sheffield boasts five Nobel Prize winners among former staff and students. Its alumni have gone on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.

Research partners and clients include Boeing, Rolls-Royce, Unilever, Boots, AstraZeneca, GSK, Siemens, Yorkshire Water and many more household names, as well as UK and overseas government agencies and charitable foundations.

The University has well-established partnerships with a number of universities and major corporations, both in the UK and abroad.

Contact For further information please contact Clare Parkin
Media Relations Officer
0114 222 9851
clare.parkin@sheffield.ac.uk